MELSMON

Product Overview

MELSMON Injection is a Japanese prescription pharmaceutical product containing a hydrolyzed extract derived from human placenta. Manufactured by Melsmon Pharmaceutical Co., Ltd. in Japan, each 2 mL ampoule contains human placental extract equivalent to 100 mg of water-soluble placental constituents. MELSMON is authorized for the treatment of menopausal disorders in Japan and South Korea, with an additional approved indication for insufficient lactation in Japan.

MELSMON is a human placenta-derived injectable medicine with a long history of pharmaceutical use in Japan, where it was first introduced in 1956. The product contains a complex mixture of water-soluble substances obtained from human placental tissue, including various amino acids.

Unlike synthetic single-molecule pharmaceuticals, MELSMON is characterized by its biologically derived composition. Its active ingredient is identified as human placental extract rather than an individually isolated peptide, growth factor, hormone, or other specific molecular compound.

MELSMON is supplied as a ready-to-use aqueous solution in 2 mL glass ampoules. Documented manufacturer packaging includes boxes containing 10 or 50 ampoules, although available commercial configurations differ by market.

This TEOSQUARE product page provides professional buyers with verified information about MELSMON's pharmaceutical composition, Japanese manufacturing origin, ampoule specifications, approved indications, packaging, storage requirements, and biological-product safety considerations.

Key Features

• Human Placenta-Derived Extract: Contains a pharmaceutical extract prepared from human placental tissue, with 100 mg of water-soluble placental constituents per 2 mL ampoule.
• Japanese Pharmaceutical Product: Manufactured by Melsmon Pharmaceutical Co., Ltd., a Japanese pharmaceutical company specializing in placenta-derived products.
• Established Pharmaceutical History: MELSMON was first marketed in Japan in 1956 and has an established history of use within the country's regulated pharmaceutical system.
• Ready-to-Use Liquid Formulation: Supplied as an aqueous injection solution in individual 2 mL ampoules rather than a lyophilized powder.
• 10- and 50-Ampoule Presentations: Japanese prescribing information documents packages containing 10 or 50 ampoules, while the Korean product holder currently identifies a 50-ampoule commercial package.
• Prescription Pharmaceutical Classification: Registered as a prescription medicine in Japan and South Korea, with approved indications and professional-use requirements defined by the respective national authorities.

Composition & Specifications

MELSMON contains human placental extract as its active pharmaceutical ingredient. The Japanese prescribing information specifies 100 mg of water-soluble substances derived from human placental chorionic tissue per 2 mL ampoule.

The formulation also contains benzyl alcohol as an excipient. The Japanese pharmaceutical label identifies 0.03 mL of benzyl alcohol per 2 mL ampoule.

Human Placental Extract

The human placenta is a temporary organ that supports nutrient exchange, gas exchange, and other physiological processes during pregnancy.

Placental tissue contains a variety of biological substances, including proteins, amino acids, lipids, carbohydrates, and other naturally occurring compounds.

MELSMON is manufactured using human placental tissue as its starting material. The resulting pharmaceutical extract contains water-soluble constituents rather than intact placental tissue.

The Japanese pharmaceutical specification identifies 100 mg of water-soluble placental constituents per ampoule. This quantity describes the standardized extract content and should not be interpreted as 100 mg of a single purified protein, growth factor, or peptide.

Amino Acid Components

The Japanese prescribing information identifies multiple amino acids among the quantifiable constituents of MELSMON.

These include lysine, alanine, aspartic acid, leucine, glutamic acid, glycine, valine, serine, tyrosine, phenylalanine, threonine, arginine, proline, isoleucine, methionine, and histidine.

Amino acids are essential components of biological proteins and participate in numerous physiological processes.

However, the presence of amino acids within a complex placental extract does not independently establish enhanced collagen synthesis, increased skin elasticity, accelerated tissue regeneration, or other specific cosmetic benefits.

Complex Biological Composition

Unlike pharmaceutical products containing a single chemically defined active compound, MELSMON contains a complex mixture of placenta-derived constituents.

The Japanese prescribing information states that the active ingredient cannot be characterized as one specific substance because the extract contains multiple trace components.

Accordingly, descriptions of MELSMON as a purified growth factor injection, stem cell product, exosome formulation, or hormone replacement therapy would not accurately represent its registered pharmaceutical composition.

Benzyl Alcohol

Benzyl alcohol is included as an excipient in the MELSMON formulation.

The Japanese pharmaceutical label specifies 0.03 mL of benzyl alcohol per 2 mL ampoule. Benzyl alcohol is used in pharmaceutical preparations for formulation-related purposes and is not the principal therapeutic ingredient.

Its presence is clinically relevant because benzyl alcohol-containing injectable products require additional precautions in certain patient populations, particularly neonates and premature infants.

MELSMON's active ingredient is a complex human placenta-derived extract. Claims involving specific concentrations of growth factors, cytokines, hormones, or individual peptides should not be attributed to the finished product without manufacturer-verified analytical documentation.

How MELSMON Works

MELSMON contains multiple water-soluble constituents derived from human placental tissue. Its complete pharmacological mechanism has not been fully established.

The Japanese prescribing information discusses several biological activities investigated in experimental research, including cellular respiration, wound-healing processes, and fatigue-related responses.

Cellular Metabolic Activity

Cellular respiration refers to biochemical processes through which cells generate energy from metabolic substrates.

Experimental research cited in the Japanese pharmaceutical documentation investigated the effects of MELSMON on tissue respiration in isolated rat liver preparations.

These findings provide historical pharmacological context but do not establish that MELSMON increases human mitochondrial ATP production, reverses biological aging, or improves general metabolic health.

Tissue Repair and Wound-Healing Research

Certain preclinical investigations have examined placenta-derived preparations in experimental tissue-injury models.

The Japanese prescribing information describes experimental observations involving wound-healing responses in animal models.

However, preclinical tissue-repair findings cannot be directly translated into claims that MELSMON produces clinical skin regeneration, wrinkle reduction, scar improvement, or enhanced collagen production.

Fatigue-Related Experimental Research

Animal research referenced in Japanese pharmaceutical documentation has also investigated fatigue-related outcomes following administration of MELSMON.

Such observations do not establish clinical effectiveness for generalized fatigue, physical performance, wellness enhancement, or recovery from everyday stress.

Clinical Pharmacology and Evidence Limitations

The full mechanism underlying MELSMON's approved therapeutic effects remains incompletely understood.

Its pharmaceutical authorization is based on the product's specific regulatory evaluation rather than a demonstrated ability to activate a single molecular pathway.

No particular individual component of the placental extract should be presented as solely responsible for the finished product's therapeutic activity without supporting evidence.

The biological activities described above are based primarily on experimental research and historical pharmaceutical investigations. They do not establish independent clinical efficacy for cosmetic anti-aging, skin whitening, hair restoration, or general rejuvenation.

Approved Indications & Clinical Information

MELSMON is a prescription pharmaceutical product with country-specific approved indications. The product's authorized use in Japan differs from its registered indication in South Korea.

Menopausal Disorders

MELSMON is approved in Japan and South Korea for the treatment or improvement of symptoms associated with menopausal disorders.

Menopausal disorders may involve symptoms such as hot flashes, sleep disturbances, fatigue, irritability, and other physical or psychological changes occurring during the menopausal transition.

The Japanese prescribing information describes post-marketing clinical research involving 31 patients with menopausal disorders.

In that study, 24 of 31 patients were classified as responding to treatment, corresponding to a reported response rate of 77.4%.

This result reflects a specific clinical study and should not be interpreted as a guaranteed response rate for every patient or clinical setting.

Insufficient Lactation

In Japan, MELSMON is also approved for insufficient lactation, a condition involving inadequate breast milk production after childbirth.

The Japanese prescribing information describes a post-marketing clinical study involving 67 first-time mothers experiencing insufficient lactation.

A response was reported in 46 of 67 participants, corresponding to 68.6%.

This indication is documented in Japanese pharmaceutical labeling. It should not automatically be considered an approved indication in South Korea or other countries.

Cosmetic and Aesthetic Applications

Human placental extracts are sometimes discussed in the medical aesthetics industry in connection with skin conditioning, pigmentation, aging, and general wellness.

However, MELSMON's established pharmaceutical registrations do not identify cosmetic skin whitening, wrinkle reduction, hair regeneration, or general anti-aging as approved indications.

Evidence involving other placental extracts, cosmetic formulations, or experimental preparations cannot automatically establish comparable clinical effects for MELSMON Injection.

Approved indications vary by jurisdiction. Japan recognizes menopausal disorders and insufficient lactation, while the current South Korean pharmaceutical labeling identifies improvement of menopausal disorder symptoms. Professional buyers must verify the applicable labeling in their destination market.

Packaging & Product Presentation

MELSMON is supplied as a ready-to-use aqueous injection solution in individual 2 mL glass ampoules.

The Japanese manufacturer documents commercial packages containing 10 or 50 ampoules. The current South Korean product holder identifies a 50-ampoule package in its registered product information.

Product labeling, ampoule appearance, and commercial packaging may differ between Japanese domestic distribution and authorized export markets.

The Japanese prescribing information describes MELSMON as a clear, pale-yellow liquid, while the Korean registration describes a clear, light-brown solution contained in a brown ampoule.

Professional buyers should verify the original product name, ampoule volume, package quantity, batch number, expiration date, manufacturer information, and market-specific pharmaceutical labeling.

The 2 mL ampoule volume is a product packaging specification. It does not authorize alternative administration routes or establish a treatment recommendation. Commercial package quantities must be verified against the actual supplied presentation.

Storage & Handling

MELSMON must be stored according to the original pharmaceutical labeling applicable to its destination market.

The current South Korean registration specifies storage in sealed containers at 1°C to 30°C, with a shelf life of 24 months from manufacture. Japanese prescribing information specifies room-temperature storage and a shelf life of three years.

• South Korean Storage Requirements: Store in a sealed container between 1°C and 30°C.
• Japanese Storage Requirements: Store at room temperature according to the Japanese prescribing information.
• Shelf Life: The registered shelf life is 24 months in South Korea and three years in Japan. Follow the expiration date on the supplied product.
• Ampoule Integrity: Inspect the glass ampoule and its original packaging for cracks, leakage, damage, or other signs of compromised integrity.
• Product Traceability: Verify the batch number, expiration date, manufacturer information, and applicable biological-product documentation.

MELSMON contains human-derived biological material. Applicable regulations may therefore require additional documentation, handling controls, and product traceability.

The shelf-life difference between Japan and South Korea reflects market-specific registered information. The expiration date and storage instructions on the supplied product take precedence over generalized commercial descriptions.

Safety & Regulatory Considerations

MELSMON is a prescription medicine derived from human placental tissue. Its use requires appropriate medical supervision and compliance with the product's official indications, contraindications, administration restrictions, and national pharmaceutical regulations.

Human Biological Material and Infection Risk

MELSMON is manufactured from donated human placental tissue.

The Japanese manufacturer describes donor screening, infectious disease testing, and validated manufacturing processes intended to reduce the risk of transmitting infectious agents.

These procedures include screening for selected viral infections and manufacturing controls designed to inactivate or remove potential contaminants.

Nevertheless, the Japanese and South Korean prescribing information explicitly states that the possibility of infection transmission from human-derived biological material cannot be completely excluded.

Treatment decisions should account for this residual risk and the established medical necessity of the product.

Potential Adverse Reactions

Reported adverse reactions associated with MELSMON include injection-site pain, redness, chills, nausea, fever, rash, and other hypersensitivity reactions.

Serious reactions, including shock, have also been identified in the product's pharmaceutical safety information.

Individuals with a history of hypersensitivity to MELSMON or its components may have contraindications to treatment.

Benzyl Alcohol Precautions

MELSMON contains benzyl alcohol as an excipient. The South Korean prescribing information includes warnings concerning serious adverse reactions associated with benzyl alcohol exposure in premature infants.

The product must not be assumed suitable for neonatal or pediatric use.

Authorized Administration Route

MELSMON's Japanese and South Korean pharmaceutical labeling identifies subcutaneous injection as the authorized administration route.

The existence of commercial discussions involving intravenous infusion, mesotherapy, or other aesthetic applications does not establish approval for those administration methods.

This product description does not provide preparation or injection instructions.

Biological Product Traceability

In Japan, MELSMON is classified as a specified biological product. This classification carries additional traceability and recordkeeping requirements.

Japanese prescribing information requires relevant treatment and product-identification records to be retained for at least 20 years.

Blood donation eligibility following MELSMON treatment is also subject to national rules. Under the Japanese criteria effective October 1, 2026, individuals who have received MELSMON Injection may donate blood after three months have elapsed since their last administration, subject to other eligibility requirements.

International Regulatory Authorization

MELSMON has pharmaceutical registrations in Japan and South Korea, but these authorizations do not establish equivalent approval in the United States, European Union, or other markets.

Professional buyers should verify the product's local registration status, prescription requirements, import eligibility, lawful distribution arrangements, and permitted clinical indications before procurement.

MELSMON is a regulated prescription pharmaceutical product, not a general cosmetic injectable. This description is intended for professional product identification and comparison and does not establish patient suitability or authorize unapproved medical or aesthetic applications.

Frequently Asked Questions